Pre-earnings options volume in Recursion Pharmaceuticals is 2.0x normal with calls leading puts 19:5. Implied volatility suggests the market is anticipating a move near 14.8%, or $2.29, after results are released. Median move over the past eight quarters is 2.6%.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RXRX:
- RXRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Recursion to Host Public L(earnings) Call on February 27
- SoundHound, Nano-X Imaging jump after Nvidia details holdings
- Cathie Wood’s ARK Investment bought 519K shares of Recursion Pharmaceuticals
- Recursion Pharmaceuticals Restructures Executive Leadership Team